Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87%), event free-survival (75%) and overall survival (63%) compared with historical patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.10892 | DOI Listing |
Publication Analysis
Top Keywords
dose dense
8
primary breast
8
breast lymphoma
8
rituximab dose
4
dense chemotherapy
4
chemotherapy primary
4
lymphoma treatment
4
treatment primary
4
lymphoma pbl
4
pbl remains
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!